Ottawa, Canada – Health Canada has requested an Indian drug company to stop product shipment to Canada after the United States Food and Drug Administration (FDA) recently reviewed the company’s manufacturing practices.
Drug companies normally design and manufacture drugs and medications for animal and human consumption. Prescription medications or otherwise serve as an urgent care near me relief among people who need it, and these drugs are intended as an urgent care and treatment among ill patients. Thus, proper practice in a drug company’s manufacturing and distribution methods is vital.
On that note, the U.S. FDA found falsified and manipulated data provided by IPCA, an Indian pharmaceutical company. The same company is a manufacturer of 350 different drug formulations. IPCA did not dispute with Health Canada with the falsification and manipulation findings by the FDA. Thus, Health Canada has ordered IPCA to stop product shipment of its products in the country. The findings involved nearly 21 active pharmacological ingredients.
Additionally, the federal department ordered Canadian companies that imported IPCA products from any IPCA facilities, which contained the active ingredients to quarantine the products temporarily. Consuming those health products might require the consumer to visit an urgent care clinic, considering the probable harm it could cause.
However, there has been no any indication that those products identified and under inspection by the FDA could pose possible health risks. That is why both the FDA and Health Canada has not requested for any recall of the products from the market.
The agency added that Health Canada will work with other offices, urgent care clinics, Canadian importers, international regulators, and IPCA in gathering further information about the affected products. Product testing will be done, as well as the assessment of the products’ necessity, market share, and risks, a process which will be completed within a few weeks.
Health Canada’s order to stop product shipment from IPCA is only temporary, but Health Canada advisory has also indicated the unexpected, immediate control on the product availability. The health department said it will work with other provinces and territories in monitoring the supply situation, and develop mitigation strategies, if and when necessary.
IPCA, the 60-year old company identified its global pharmaceutical clients, including Sanofi Aventis, Roche, Merck, GSK, and AstraZeneca. Consequently, Health Canada pointed out that the stop product shipment order and voluntary quarantine continue up until adequate measures are satisfied, confirming the products’ quality of IPCA facilities.